Results 81 to 90 of about 238,915 (301)

Macrophage Membrane‐Cloaked, ROS‐Triggered Quercetin Nanocarriers Target Ovarian Lesions to Treat Polycystic Ovary Syndrome

Advanced Healthcare Materials, EarlyView.
The synthesis process of MM@PCD@QNPs and its potential mechanism for treating PCOS. (A) Assembly steps of MM@PCD@QNPs. (B) Synthesis and decomposition of MM@PCD@QNPs. (C) Potential therapeutic mechanisms of MM@PCD@QNPs for PCOS. PCD, PABP conjugated with DEX polymer; QUR, quercetin; CDI, N, N′‐carbonyldiimidazole; DEX, dextran; PABP, 4‐(hydroxymethyl ...
Wenzhu Li, Yu Guan, Nan Song, Feng Zhang, Zhimin Deng, Tailang Yin, Yanbing Yang, João Conde, Wenyi Jin, Zhinang Yin   +9 more
wiley   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Apolipoprotein E and Atherosclerosis: From Lipoprotein Metabolism to MicroRNA Control of Inflammation. [PDF]

, 2018
Apolipoprotein (apo) E stands out among plasma apolipoproteins through its unprecedented ability to protect against atherosclerosis. Although best recognized for its ability to mediate plasma lipoprotein clearance in the liver and protect against ...
Hasty, Hui, Hussain, Lin, Mahley, Pepe, Roselaar   +6 more
core   +2 more sources

Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein [PDF]

Clinical Chemistry, 1998
Abstract Cardiovascular disease is the leading cause of morbidity and mortality in Westernized populations. Evolving lipoprotein risk factors include LDL oxidation and lipoprotein(a) [lp(a)]. Several lines of evidence support a role for oxidatively modified LDL in atherogenesis and its in vivo existence.
openaire   +2 more sources

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

Advanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang, Wing Yan Chung, Serena M. Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M. Morrow, Ilka Lorenzen‐Schmidt, Fengxia Xiao, Augusto Zani, Dylan Burger, Hye Kyoung Sung, Erin E. Mulvihill, Gary Sweeney   +13 more
wiley   +1 more source

The Role of High Density Lipoproteins in Thrombosis

The Scientific World Journal, 2002
Lipids and lipoproteins, as well as factors involved in hemostasis and thrombosis, play a central role in the pathogenesis of cardio- and cerebrovascular disease.
Marina Cuchel, Daniel J. Rader
doaj   +1 more source

Lipid transfer between human serum high density lipoproteins and egg yolk lipoproteins in incubation mixtures

Journal of Lipid Research, 1966
Ultracentrifugally isolated human serum high density lipoproteins of d 1.063-1.21 (HDL) were incubated with egg yolk lipoproteins of d < 1.006 for up to 24 hr at various concentrations. Transfer of HDL cholesterol esters to egg yolk lipoproteins occurred
Alex V. Nichols, Elaine L. Coggiola
doaj   +1 more source

CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads

Advanced Healthcare Materials, EarlyView.
In this paper researchers introduce CORE LNPs, a new class of lipid nanoparticles engineered to redirect mRNA expression away from the liver and into the spleen, a key immune organ. By combining chemical design with computational tools, they created cholesterol analogs that enable precise spleen‐targeted expression, providing greater applications for ...
Eshan A. Narasipura, Vincent Fung, Rachel VanKeulen‐Miller, Palas B. Tiwade, Owen S. Fenton   +4 more
wiley   +1 more source

Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100.

Journal of Lipid Research, 1992
A monoclonal antibody to apolipoprotein (apo) B-100 (JI-H) with unique binding properties has been used to separate a population of triglyceride-rich lipoproteins from blood plasma of normotriglyceridemic individuals and patients with various forms of ...
E Campos, K Nakajima, A Tanaka, RJ Havel
doaj   +1 more source

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

Advanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen, Neona M. Lowe, Sophia Kellogg, Kuan‐Wei Huang, Hannah O'Toole, Elizabeth J. Hale, Venktesh S. Shirure, Bhupinder S. Shergill, Steven C. George, Randy P. Carney   +9 more
wiley   +1 more source